TTY Biopharm Company Limited(TW:4105)
NT$82.10-0.10 (-0.12%)
TW:4105
TTY Biopharm Company Limited financials statements
NT$82.10
At close:-0.10 (-0.12%)
TTY Biopharm Company Limited (4105) Ratios
TTY Biopharm Company Limited Ratios
TW:4105's free cash flow for Q2 2026 was NT$175.25M. For the 2026 fiscal year, TW:4105's free cash flow was decreased by NT$-34.30M and operating cash flow was NT$209.54M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.28 | 2.02 | 2.08 | 1.73 | 1.56 |
| Quick Ratio | 1.75 | 1.58 | 1.65 | 1.37 | 1.24 |
| Cash Ratio | 0.95 | 0.97 | 1.01 | 0.81 | 0.73 |
| Solvency Ratio | 0.53 | 0.49 | 0.39 | 0.38 | 0.28 |
| Operating Cash Flow Ratio | 0.67 | 0.47 | 0.42 | 0.42 | 0.41 |
| Short-Term Operating Cash Flow Coverage | 1.46 | 0.82 | 0.72 | 0.67 | 0.58 |
| Net Current Asset Value | NT$ 2.71B | NT$ 2.44B | NT$ 2.00B | NT$ 1.67B | NT$ 1.22B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.11 | 0.16 | 0.19 | 0.19 | 0.24 |
| Debt-to-Equity Ratio | 0.17 | 0.26 | 0.32 | 0.33 | 0.43 |
| Debt-to-Capital Ratio | 0.14 | 0.21 | 0.24 | 0.25 | 0.30 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.01 | 0.06 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.57 | 1.61 | 1.66 | 1.70 | 1.80 |
| Debt Service Coverage Ratio | 1.15 | 0.81 | 0.88 | 0.64 | 0.40 |
| Interest Coverage Ratio | 44.08 | 35.98 | 38.90 | 53.20 | 58.64 |
| Debt to Market Cap | 0.06 | 0.10 | 0.10 | 0.09 | 0.13 |
| Interest Debt Per Share | 4.79 | 7.24 | 7.84 | 7.61 | 8.93 |
| Net Debt to EBITDA | -0.68 | -0.59 | -0.43 | -0.33 | -0.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 57.66% | 57.94% | 58.55% | 59.69% | 61.03% |
| EBIT Margin | 26.41% | 25.86% | 26.42% | 25.98% | 24.39% |
| EBITDA Margin | 29.45% | 29.30% | 30.07% | 29.66% | 25.10% |
| Operating Profit Margin | 26.41% | 23.65% | 24.98% | 24.34% | 24.54% |
| Pretax Profit Margin | 32.93% | 31.99% | 25.78% | 25.52% | 23.97% |
| Net Profit Margin | 24.16% | 24.60% | 20.50% | 21.62% | 18.34% |
| Continuous Operations Profit Margin | 25.64% | 25.78% | 20.32% | 19.49% | 18.14% |
| Net Income Per EBT | 73.36% | 76.88% | 79.50% | 84.71% | 76.50% |
| EBT Per EBIT | 124.72% | 135.29% | 103.20% | 104.88% | 97.68% |
| Return on Assets (ROA) | 13.74% | 13.34% | 11.43% | 11.40% | 8.95% |
| Return on Equity (ROE) | 21.54% | 21.47% | 18.99% | 19.34% | 16.10% |
| Return on Capital Employed (ROCE) | 19.57% | 17.42% | 18.86% | 18.43% | 17.83% |
| Return on Invested Capital (ROIC) | 13.37% | 11.64% | 12.31% | 11.02% | 9.99% |
| Return on Tangible Assets | 14.27% | 13.82% | 11.62% | 11.70% | 9.07% |
| Earnings Yield | 7.25% | 8.01% | 5.63% | 5.28% | 4.86% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.15 | 4.28 | 4.01 | 4.03 | 3.94 |
| Payables Turnover | 10.46 | 8.99 | 9.57 | 9.01 | 13.59 |
| Inventory Turnover | 1.97 | 1.95 | 2.08 | 1.96 | 1.85 |
| Fixed Asset Turnover | 2.91 | 2.58 | 2.39 | 2.07 | 1.80 |
| Asset Turnover | 0.57 | 0.54 | 0.56 | 0.53 | 0.49 |
| Working Capital Turnover Ratio | 2.05 | 2.06 | 2.25 | 2.65 | 2.30 |
| Cash Conversion Cycle | 238.58 | 231.65 | 228.15 | 236.03 | 263.01 |
| Days of Sales Outstanding | 87.92 | 85.27 | 91.00 | 90.63 | 92.66 |
| Days of Inventory Outstanding | 185.55 | 186.98 | 175.31 | 185.91 | 197.20 |
| Days of Payables Outstanding | 34.88 | 40.60 | 38.15 | 40.51 | 26.85 |
| Operating Cycle | 273.47 | 272.25 | 266.30 | 276.54 | 289.86 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.68 | 5.43 | 4.36 | 4.97 | 5.05 |
| Free Cash Flow Per Share | 6.10 | 4.89 | 3.96 | 4.42 | 4.75 |
| Dividend Paid and CapEx Coverage Ratio | 1.47 | 1.34 | 1.15 | 1.40 | 1.18 |
| Capital Expenditure Coverage Ratio | 11.68 | 10.05 | 10.90 | 9.12 | 16.94 |
| Operating Cash Flow Coverage Ratio | 1.44 | 0.77 | 0.57 | 0.66 | 0.57 |
| Operating Cash Flow to Sales Ratio | 0.27 | 0.23 | 0.20 | 0.24 | 0.28 |
| Free Cash Flow Yield | 7.49% | 6.71% | 4.92% | 5.31% | 6.91% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.00 | 12.49 | 17.75 | 18.95 | 20.54 |
| Price-to-Sales (P/S) Ratio | 3.33 | 3.07 | 3.64 | 4.10 | 3.77 |
| Price-to-Book (P/B) Ratio | 2.97 | 2.68 | 3.37 | 3.66 | 3.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 13.35 | 14.90 | 20.33 | 18.85 | 14.47 |
| Price-to-Operating Cash Flow Ratio | 12.21 | 13.41 | 18.47 | 16.78 | 13.62 |
| Price-to-Earnings Growth (PEG) Ratio | 1.72 | 0.44 | 5.58 | 0.60 | -2.06 |
| Enterprise Value Multiple | 10.64 | 9.90 | 11.68 | 13.49 | 15.01 |
| Enterprise Value | 20.21B | 17.09B | 19.34B | 20.25B | 17.09B |
| EV to EBITDA | 10.64 | 9.90 | 11.68 | 13.49 | 15.01 |
| EV to Sales | 3.13 | 2.90 | 3.51 | 4.00 | 3.77 |
| EV to Free Cash Flow | 12.55 | 14.07 | 19.62 | 18.40 | 14.45 |
| EV to Operating Cash Flow | 11.47 | 12.67 | 17.82 | 16.39 | 13.60 |
| Tangible Book Value Per Share | 28.90 | 28.71 | 25.51 | 24.06 | 22.69 |
| Shareholders’ Equity Per Share | 27.43 | 27.15 | 23.89 | 22.76 | 20.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.22 | 0.19 | 0.21 | 0.24 | 0.24 |
| Revenue Per Share | 24.45 | 23.70 | 22.14 | 20.36 | 18.24 |
| Net Income Per Share | 5.91 | 5.83 | 4.54 | 4.40 | 3.35 |
| Tax Burden | 0.73 | 0.77 | 0.80 | 0.85 | 0.77 |
| Interest Burden | 1.25 | 1.24 | 0.98 | 0.98 | 0.98 |
| Research & Development to Revenue | 0.03 | 0.05 | 0.06 | 0.07 | 0.06 |
| SG&A to Revenue | 0.28 | 0.30 | 0.29 | 0.28 | 0.29 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.83 | 0.72 | 0.76 | 1.13 | 1.16 |
Currency in TWD
